摘要
目的:观察安罗替尼胶囊联合长春瑞滨软胶囊治疗晚期非小细胞肺癌的的疗效及安全性。方法:选择病理确诊的ⅢB/Ⅳ期非小细胞肺癌病人,口服安罗替尼胶囊(12 mg),1次/天,连续14 d,联合口服长春瑞滨软胶囊(60 mg/m^(2))第1天及第8天,21 d为1个周期,直至疾病进展或毒性不能耐受。记录病人客观反应率、疾病控制率、无进展生存期、总生存期及不良反应。结果:共纳入研究30例病人,无完全缓解病例,部分缓解4例,疾病稳定21例,疾病进展5例。客观缓解率为13.3%,疾病控制率为83.3%。中位无进展生存期为6.5个月(6.3~6.9个月);中位总生存期为9.9个月(7.7~11.7个月)。在影响进展及死亡的单因素分析中,年龄≥60岁、PS评分为0~1分、无吸烟史、病理类型为腺癌病人的中位无进展生存时间和中位生存时间均分别高于年龄<60岁、PS评分为2分、有吸烟史、病理类型为鳞癌组的病人(P<0.05~P<0.01)。最常见的不良反应为恶心、呕吐,发生率为36.7%,疲乏的发生率为33.3%,腹泻的发生率为30%,但多为1~2级,对症治疗后改善。结论:安罗替尼胶囊联合长春瑞滨软胶囊双口服药物对晚期非小细胞肺癌可达到较好的控制疾病进展,延长病人生存期的目的,且不良反应可控。
Objective:To observe the efficacy and safety of anlotinib capsule combined with vinorelbine soft capsule in the treatment of advanced non-small cell lung cancer(NSCLC).Methods:The patients with stageⅢB/ⅣNSCLC confirmed by pathology were treated with anlotinib capsule(12 mg)once a day for 14 days,and combined with vinorelbine soft capsule(60 mg/m^(2))orally on day 1 and day 8,21 days for a cycle,and until disease progression or toxicity became intolerant.The objective response rates,disease control rates,progression-free survival,overall survival and adverse reactions were recorded.Results:A total of 30 patients were included in this study,which included no complete response cases,4 partial response cases,21 stable disease cases and 5 progressive disease cases.The objective remission rate was 13.3%,and the disease control rate was 83.3%.The median progression-free survival was 6.5(6.3-6.9)months,and the median overall survival was 9.9(7.7-11.7)months.In the univariate analysis affecting progression and death,the median progression-free survival time and median survival time in patients with≥60 years old,PS score for 0-1,no smoking history and pathological type of adenocarcinoma were higher than those in patients with age<60 years old,PS score for 2,smoking history and pathological type of squamous cell carcinoma(P<0.05 to P<0.01).The nausea and vomiting(36.7%),fatigue(33.3%)and diarrhea(30%)were the most common adverse reactions,but most of them were grade 1 or 2,which could be improved after symptomatic treatment.Conclusions:The anlotinib capsule combined with vinorelbine soft capsule in the treatment of NSCLC can better control the disease progression,achieve the purpose of prolonging the patient's survival time,and the adverse reactions can be controlled.
作者
解华
刘宏杰
舒桂君
XIE Hua;LIU Hong-jie;SHU Gui-jun(Department of Oncology,Xuancheng People's Hospital,Xuancheng Anhui 242000,China)
出处
《蚌埠医学院学报》
CAS
2021年第8期1045-1049,1053,共6页
Journal of Bengbu Medical College
关键词
非小细胞肺癌
安罗替尼胶囊
长春瑞滨软胶囊
口服
疗效
non-small cell lung cancer
anlotinib capsule
vinorelbine soft capsule
oral
curative effect
